Trial Profile
Efficacy and Safety of Xience in Coronary artery disease all-comers after stenting using the PRIME platform.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EXCELLENT-PRIME Registry
- 30 Aug 2017 Results comparing biodegradable-polymer biolimus A9-eluting stents and durable polymer drug-eluting stents from this and other registries in Korea, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 01 Jun 2012 New trial record